{"url":"https://lda.gov/api/v1/filings/4707a023-1030-402d-9158-ce5f6ce00d1f/","filing_uuid":"4707a023-1030-402d-9158-ce5f6ce00d1f","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4707a023-1030-402d-9158-ce5f6ce00d1f/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-07-20T16:25:16-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":196641,"url":"https://lda.gov/api/v1/clients/196641/","client_id":1356,"name":"NOVARTIS, INC.","general_description":"Multinational biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-03-26"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57923,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"FORBES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":58264,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"STRUNK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[{"name":"NOVARTIS INTERNATIONAL AG","contribution":"0.00","ownership_percentage":"100.00","address":"Forum 1, Novartis Campus, CH-4056","city":"Basel","state":null,"state_display":null,"country":"CH","country_display":"Switzerland","ppb_city":"Basel","ppb_state":null,"ppb_state_display":null,"ppb_country":"CH","ppb_country_display":"Switzerland"}],"affiliated_organizations":[]}